Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $6.69 Million
Wall Street analysts predict that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will report $6.69 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with estimates ranging from $4.50 million to $8.80 million. Pieris Pharmaceuticals reported sales of $18.15 million during the same quarter last year, which indicates a negative year-over-year growth rate of 63.1%. The company is expected to issue its next earnings report on Friday, March 8th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $30.66 million for the current year, with estimates ranging from $28.70 million to $33.00 million. For the next financial year, analysts expect that the firm will report sales of $22.74 million, with estimates ranging from $12.00 million to $31.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. The business had revenue of $8.35 million during the quarter, compared to analyst estimates of $6.16 million.
In other news, Director Christopher P. Kiritsy bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were purchased at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $51,100. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 5.07% of the company’s stock.
Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its holdings in shares of Pieris Pharmaceuticals by 2.0% during the 3rd quarter. Acadian Asset Management LLC now owns 2,167,227 shares of the biotechnology company’s stock worth $12,136,000 after purchasing an additional 42,354 shares during the period. Alpine Global Management LLC increased its holdings in shares of Pieris Pharmaceuticals by 125.0% during the 2nd quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 25,000 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Pieris Pharmaceuticals by 1,516.2% during the 2nd quarter. GSA Capital Partners LLP now owns 269,900 shares of the biotechnology company’s stock worth $1,368,000 after purchasing an additional 253,200 shares during the period. Aquilo Capital Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $10,013,000. Finally, BlueMountain Capital Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $500,000. Institutional investors own 65.36% of the company’s stock.
Shares of PIRS stock remained flat at $$3.51 on Wednesday. 428,334 shares of the company traded hands, compared to its average volume of 569,235. Pieris Pharmaceuticals has a 1-year low of $3.04 and a 1-year high of $9.75. The firm has a market cap of $190.07 million, a price-to-earnings ratio of -8.78 and a beta of 1.88.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Further Reading: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.